Thank you for your generous support of the C-TRAK trials at The Royal Marsden.

“Thank you for your generous support of the C-TRAK trials at The Royal

Marsden. I understand that you require an update on the project’s

progress for your website. Would the following summary suit your


_”55,000 women will be diagnosed with breast cancer each year, and

around 15% of these cases will be triple negative breast cancer

(TNBC). TNBC does not respond to common therapies such as tamoxifen or

Herceptin and has a high rate of recurrence. Relapsed TNBC is often

not visible on a CT or MRI scan until it is too large to be treated.

Funding from Breast Cancer Research Aid has enabled a clinical trial –

C-TRAK – which is trying to improve diagnosis and treatment for TNBC.

The first part of the trial is attempting to identify relapsed TNBC

before it is too late to be treated by identifying specific

circulating tumour DNA (ctDNA) in the patients’ blood. Patients’ with

TNBC will have their blood tested every three months for two years in

the hope of using the ctDNA to identify a relapse in their condition.

Any patients who are found to have relapsed will then be randomized

into the second part of the trial which will see them either observed

or receiving pembrolizumab for one year._

_As of October 2019, C-TRAK has recruited 180 patients with TNBC. Our

target is to recruit 200 patients, and so we will be able to begin

ctDNA surveillance soon.”_

Please don’t hesitate to contact me if you need any further


Kind regards,

Sarah Kennedy

Sarah Kennedy

Philanthropy Executive – Trusts

The Royal Marsden Cancer Charity

0207 811 8046


Read more

The Royal Marsden Hospital

We are very grateful to Breast Cancer Research Aid for your support of The Royal Marsden’s C-TRAK trial, an innovative research project that has the potential to change the lives of women diagnosed with triple negative breast cancer in the UK and world-wide.

The Royal Marsden was founded thanks to contemporary philanthropists and your generosity is continuing this important tradition. Thank you for helping us to drive forward advances in breast cancer research and provide patients with the best quality of life.

C-TRAK: Developing a novel way to detect and treat breast cancer
Breast cancer is the most common cancer in the UK, with around 55,000 women diagnosed every year. Of those women, 15 per cent will be diagnosed with triple negative breast cancer (TNBC).

Standard treatment for this type of cancer includes surgery and chemotherapy. However, TNBC is difficult to treat because it does not respond to common therapies, such as tamoxifen or Herceptin.

Furthermore, TNBC is more likely to recur than other breast cancers. Sadly, by the time TNBC returns and has grown large enough to be seen on a CT or MRI scan, the disease is often untreatable.

To meet this challenge, The Royal Marsden is leading C-TRAK: a two-part clinical trial that will assess if a blood test can detect TNBC as soon as it recurs and investigate a new therapy option to successfully treat the disease before it becomes life-threatening.

Read More…

Read more

The Institute Of Cancer Research (ICR), London

Through the support of Breast Cancer Research Aid, the Institute of Cancer Research has been able to make novel discoveries in the treatment of breast cancer. ICR focuses on uncovering cancer drugs and combination therapies through ongoing research. The research also intends to look into pathways of cancer development and ultimately what modifications lead to drug-resistance. Thus, guiding us toward better imaging modalities. With the help of Breast Cancer Research Aid, our researchers get better equipped with the latest technology and cutting-edge infrastructure.

Read more: ICR’s research into liquid biopsy tests

Read more

Cardiff University/European Cancer Stem Cell Research Institute

Cardiff University/ European Cancer Stem Cell Research Institute

With the support of Breast Cancer Research Aid, researchers at Cardiff University’s European Cancer Stem Cell Research can carry out world-leading research which has the potential to revolutionise the way we tackle cancer. The study is intended to elaborate the understanding of cancer growth and spread with the development of therapies that have high efficacy and thus, will be able to make a difference in the lives of cancer patients. Your support will help us get there faster.

Read more